Verrica Pharmaceuticals Inc (STU:1NE0)

Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €4.49 (-3.65%)

Transcript 10-Q8-K

Key Points

Positve

Verrica Pharmaceuticals Inc (VRCA) reported a 28% quarter-over-quarter increase in dispensed applicator units for YCANTH, indicating strong market demand and improved commercial execution.
The company secured a non-dilutive credit facility of up to $27.5 million from its largest shareholder, extending its cash runway into 2028 and providing financial flexibility with no scheduled interest or principal payments until 2030.
Verrica Pharmaceuticals Inc (VRCA) is advancing its pipeline, with the global Phase 3 program for common warts (YCANTH) on track for top-line data in mid-2027, and the first patient dosed in the second pivotal trial (COVE 3).
The company presented encouraging Phase 2 data for VP-315 in basal cell carcinoma, including an abscopal effect on untreated lesions, supporting its potential to change the treatment paradigm.
Verrica Pharmaceuticals Inc (VRCA) expanded its global footprint with a new distribution agreement in Israel, receiving 60% of net selling price and up to $8.2 million in milestones, complementing its partnership in Japan.

Negative

Verrica Pharmaceuticals Inc (VRCA) reported a GAAP net loss of $13.2 million in Q2 2026, a significant decline from a net income of $0.2 million in the same period last year, driven by higher R&D and SG&A expenses.
The company's cash position remains low at $11.2 million as of June 30, 2026, necessitating the new credit facility and highlighting ongoing financial strain.
Total revenue decreased to $5.9 million in Q2 2026 from $12.7 million in Q2 2025, primarily due to the absence of a one-time $8 million milestone payment received in the prior year.
The company faces seasonal headwinds in the summer months, which could impact prescription growth and revenue in the near term.
Verrica Pharmaceuticals Inc (VRCA) recognized a $1.7 million expense related to a legal settlement in Q2 2026, adding to operational costs and negatively impacting profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VRCA.OQ - Verrica Pharmaceuticals Inc
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by, your meeting is about to begin.

Good afternoon, ladies and gentlemen.

Welcome to the Verica Pharmaceuticals second quarter 2026 corporate at this time, all participants are in a mode remarks, there will be a question-and-answer session at any time, please press star 1 on your telephone.

If you would like to remove yourself from the queue, please start too.

As a reminder, this conference is being recorded.

I would now like to turn the call over to our host, Mr.

Kevin Gardner of Life Sci Advisors.

Please go ahead, sir.

Thank you, operator.

Hello everyone and welcome to Verrica Pharmaceuticals, second quarter 2026

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.